SCHEMBL17035447

SCHEMBL17035447

CC(C)(C)N1CCCN(C(C)(C)C)C1=O

nearest known ligand 0.33

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.33
LMNA P02545 1/20 0.30
MAPT P10636 1/20 0.30
PIK3CD O00329 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25136544 0.94 POLB (0.33) POLBLMNAMAPTPIK3CD
SCHEMBL611663 0.88 POLB (0.35) POLBLMNAMAPTPIK3CD
SCHEMBL9815064 0.85 BRD4 (0.39)
SCHEMBL23642177 0.80 BRD4 (0.39)
SCHEMBL19443027 0.80 PER2 (0.36) POLBPIK3CD
SCHEMBL9815041 0.79 DPP4 (0.33) POLB
SCHEMBL19443026 0.77 POLB (0.31) POLB
SCHEMBL19543655 0.77 POLB (0.31) POLB
SCHEMBL24983494 0.77 L3MBTL1 (0.37) LMNAMAPT
SCHEMBL23080561 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230387464-A1 Nonaqueous Electrolytic Solution and Nonaqueous Electrolytic Solution Battery MU IONIC SOLUTIONS CORPORATION (JP) 2023-11-30 US disclosed
US-20230387464-A1 Nonaqueous Electrolytic Solution and Nonaqueous Electrolytic Solution Battery MU IONIC SOLUTIONS CORPORATION (JP) 2023-11-30 US disclosed
US-20230121086-A1 RORgT INHIBITOR, PREPARATION METHOD THEREOF AND USE THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2023-04-20 US disclosed
US-20180016263-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME LLC 2018-01-18 US disclosed
US-20180016263-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME LLC 2018-01-18 US disclosed
US-9783527-B2 Indazole ureas and method of use ABBVIE INC. (US) 2017-10-10 US disclosed
US-9783527-B2 Indazole ureas and method of use ABBVIE INC. (US) 2017-10-10 US disclosed
US-20170283429-A1 COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS Janssen Biopharma, Inc. 2017-10-05 US disclosed
US-9724351-B2 Compounds for the treatment of paramoxyvirus viral infections ALIOS BIOPHARMA, INC. (US) 2017-08-08 US disclosed
US-9724351-B2 Compounds for the treatment of paramoxyvirus viral infections ALIOS BIOPHARMA, INC. (US) 2017-08-08 US disclosed
US-20160075692-A1 Indazole Ureas and Method of Use ABBVIE INC. (US) 2016-03-17 US disclosed
US-20150238498-A1 COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS JANSSEN PHARMACEUTICA NV (BE) 2015-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150238498-A1 COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS SARS1, MAVS, ZC3HAV1 POLB 590/4885LMNA 2538/4885MAPT 4529/4885
US-20170283429-A1 COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS MAVS, SARS1, ZC3HAV1 POLB 1400/4885LMNA 2835/4885MAPT 4377/4885
US-20180016263-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL KCNJ11, KCNJ1, SLC9A1 POLB 4703/4885LMNA 1586/4885MAPT 4238/4885
US-20160075692-A1 Indazole Ureas and Method of Use SCN8A, SCN7A, SCN3A POLB 4062/4885LMNA 1666/4885MAPT 2675/4885
US-20230121086-A1 RORgT INHIBITOR, PREPARATION METHOD THEREOF AND USE THEREOF RORC, RORB, RORA POLB 3426/4885LMNA 3977/4885MAPT 1063/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.